Palisade Bio, Inc. (PALI) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Palisade Bio, Inc.
Address
4600 South Syracuse Street
Denver, CA 80237
United States of America (the)
Phone
858 704 4900
Website
Sector
Healthcare
Industry
Biotechnology
Employees
14
First IPO Date
March 30, 2007
Key Executives
| Name | Title | Pay | Year Born |
| J. D. Finley | Chief Executive Officer, Chief Financial Officer & Director | 1.01M | 1958 |
| Mitchell Lawrence Jones | President & Chief Medical Officer | 704,000 | 1977 |
| Adarsh Patel | Head of Chemistry, Manufacturing & Controls | 0 | N/A |
| Daniel J. Larkins | Head of Global Regulatory Affairs | 0 | N/A |
| Ramesh C. Donthamsetty | Senior VP of Corporate Development & Investor Relations | 0 | N/A |
| Ryker Willie | Senior Vice President of Finance & Corporate Controller | 0 | N/A |
| Dawn Louro | VP & Head of Clinical Operations | 0 | N/A |
| Joerg Heyer | Head of Translational Science & Medicine | 0 | N/A |
| James Izanec | VP & Head of Clinical Development | 0 | N/A |
Description
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
